# A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study

> **NCT03067285** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 39 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** ELV/COBI/FTC/TAF
- **DRUG:** DTG/3TC/ABC + ELV/COBI/FTC/TAF

## Key facts

- **NCT ID:** NCT03067285
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-08
- **Primary completion:** 2019-04-23
- **Final completion:** 2019-04-23
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03067285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03067285, "A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03067285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*